Hematological Malignancies

Random. Phase III (AETHERA) BV in HL pts after auto-TX

N = 322 HL post ASCT high risk (no CR, r/r <12 mo, ex-nodal)

Placebo q3wk

Brentuximab vedotin 1.8 mg/kg q3wk

SCREENING 28 days

TREATMENT PHASE 16 three-wk cycles

FOLLOW-UP Every 12 wk

Assessments: 3, 6, 9, 12, 18, 24 mo, then every 6 mo Follow-up: every 12 wk until death

.